On the stock market since 2013, it operates in the world of health and science. It has 10,600 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $643.3M would still be left in the vault — a solid cushion for hard times.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 27% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 10% a year on average.
There is $1.5B in the vault; even if every debt were paid off, $643.3M would remain.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, RSMDF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RSMDF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.